Literature DB >> 4588969

The metabolism of antipyrine in patients with chronic renal failure.

M Lichter, M Black, I M Arias.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4588969

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN： 0022-3565            Impact factor:   4.030


× No keyword cloud information.
  10 in total

1.  Hypertrophic and hypoactive smooth endoplasmic reticulum in hepatocytes uremic patients. A morphometric and biochemical study.

Authors:  S Kawata; K Seki; Y Shinji; S Tarui; T Sugiyama; T Yamano
Journal:  Gastroenterol Jpn       Date:  1982

Review 2.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

3.  Pharmacokinetics of naproxen in subjects with normal and impaired renal function.

Authors:  M Anttila; M Haataja; A Kasanen
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

4.  The plasma half-life of antipyrine in chromic uraemic and normal subjects.

Authors:  J L Maddocks; C J Wake; M J Harber
Journal:  Br J Clin Pharmacol       Date:  1975-08       Impact factor: 4.335

5.  Assessment of liver ability to biotransformation of antipyrine in uraemic patients on regular peritoneal dialysis treatment.

Authors:  A Grzegorzewska; Z Lowicki; E Chmara; A Mrozikiewicz; K Baczyk
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

6.  Propranolol disposition in renal failure.

Authors:  A J Wood; R E Vestal; C L Spannuth; W J Stone; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1980-12       Impact factor: 4.335

7.  Antipyrine metabolite formation and excretion in patients with chronic renal failure.

Authors:  M W Teunissen; D Kampf; I Roots; N P Vermeulen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Enhancement of hepatic drug metabolism by glutethimide in patients with liver disease.

Authors:  G C Farrell; W G Cooksley; L W Powell
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

10.  Enhanced drug metabolism in cigarette smokers.

Authors:  P Hart; G C Farrell; W G Cooksley; L W Powell
Journal:  Br Med J       Date:  1976-07-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.